Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sage should be resilient amid macro uncertainty, says Citi

(Sharecast News) - Citi has reiterated a 'buy' rating for enterprise software giant Sage ahead of its interim results next week, saying that the company's "drivers of resilience" were solid despite an uncertain macro environment. Ahead of the results, Citi analyst Balajee Tirupati said the market's focus will be on customer demand and behaviour amid tough conditions, with many concerned about Sage's exposure to the small and medium-sized business (SMB) and non-profit markets in the US.

"Against this we expect a more stable business evolution with a broadly in line quarter (slight moderation in growth, better margins). Recent readthrough for SMB and back-office software space (US) appears steady, while other drivers in price increases and product expansion (regional & functionalities) remain intact," Tirupati said.

The analyst expects Sage's management to reiterate full-year guidance for growth and margins - though increased deal scrutiny by customers is possible if uncertainty persists.

"We see Sage as relatively insulated and maintain Buy on GARP appeal," Tirupati said.

Sage was trading broadly flat at 1,266p by 1102 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.